Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (Nasdaq: LBRX) announced an inducement equity award to its new Chief Commercial Officer, Kaya Pai Panandiker, granted on December 10, 2025 under the Nasdaq Listing Rule 5635(c)(4) exception. The award is an option to purchase 195,000 shares of common stock with a 10-year term and an exercise price of $21.36 per share (closing price on the grant date). The option vests over 4 years: 25% on the first anniversary and the remaining shares in equal monthly installments (1/48th) thereafter, subject to continuous service.
LB Pharmaceuticals (Nasdaq: LBRX) announced it will be added to the Russell 2000 and Russell 3000 indices, effective at the open of U.S. markets on December 22, 2025, as part of the 2025 Russell reconstitution. The company said this follows its recent IPO and comes as it is approaching initiation of key clinical trials for LB-102 in schizophrenia and bipolar depression. The Russell reconstitution ranks the 4,000 largest U.S. stocks by market capitalization as of April 30. The release notes about $10.6 trillion benchmarked to Russell US indexes (June 2024) and $18.1 trillion benchmarked to FTSE Russell indexes.
LB Pharmaceuticals (Nasdaq: LBRX) announced that CEO Heather Turner will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 at 9:30 a.m. ET.
A live webcast will be available on the company’s Investors > Events page and a replay will be archived there.
LB Pharmaceuticals (NASDAQ: LBRX) announced an inducement equity award to James Rawls upon his hiring as Senior Vice President of Regulatory Affairs.
On November 10, 2025 the company granted Mr. Rawls an option to purchase 90,000 shares of common stock under the Nasdaq Listing Rule 5635(c)(4) inducement exception. The option has a 10-year term, an exercise price of $14.61 per share (the closing price on the grant date), and vests over 4 years with 25% vesting on the first anniversary and the remainder vesting monthly at 1/48th, subject to continued service.
LB Pharmaceuticals (Nasdaq: LBRX) announced on November 12, 2025 the appointment of Kaya Pai Panandiker as Chief Commercial Officer.
Ms. Pai Panandiker brings more than 20 years of global biopharmaceutical commercial experience, including neuroscience commercialization, prior roles as Chief Commercial Officer at Neumora Therapeutics, Head of Commercial at Cerevel Therapeutics (acquired by AbbVie in 2024), and General Manager, Neuroscience at Lundbeck U.S.
The company said her experience launching and scaling global neuroscience brands will support advancement of LB-102 toward registration and commercialization.
LB Pharmaceuticals (Nasdaq: LBRX) announced that Heather Turner, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference in New York on Thursday, November 13, 2025 at 9:20 a.m. ET.
A live webcast will be available on the company’s Investors > Events page at https://ir.lbpharma.us/investors/events/, and a replay will be archived there after the presentation.
LB Pharmaceuticals (Nasdaq: LBRX) reported 3Q 2025 results and corporate updates on Nov 6, 2025. The company completed an upsized IPO of 21,850,000 shares at $15.00 raising $327.8M gross and held $314.5M cash, projected to fund operations into Q2 2028. LB-102 Phase 2 NOVA1 data showed dose-dependent cognitive effect sizes vs placebo of 0.26 (50 mg), 0.41 (75 mg) and 0.66 (100 mg). The company plans a Phase 3 acute schizophrenia trial (sample size increased from ~400 to ~460) starting in Q1 2026 with topline in H2 2027, and a potentially registrational Phase 2 bipolar depression trial starting Q1 2026 with topline in Q1 2028.
LB Pharmaceuticals (Nasdaq: LBRX) appointed James Rawls, Pharm.D. as Senior Vice President of Regulatory Affairs on October 14, 2025.
Dr. Rawls brings 25+ years of regulatory leadership, with experience at Novartis, Sunovion, Sumitomo Pharma America, and Boston Biodevelopment, and has contributed to multiple global regulatory filings and product approvals. The company said his expertise will support advancing LB-102 into a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial planned for 2026.
LB Pharmaceuticals (Nasdaq: LBRX) will present three posters at the 38th ECNP Congress (Amsterdam, Oct 11-14, 2025) reporting analyses from the Phase 2 NOVA1 trial of LB-102 in acute schizophrenia.
A post-hoc cognitive analysis showed dose-dependent, statistically significant effect sizes versus placebo at 4 weeks: 0.26 (p=0.0476) at 50 mg, 0.41 (p=0.0027) at 75 mg and 0.66 (p=0.0018) at 100 mg in a completer population. Additional posters cover primary NOVA1 efficacy/safety results and a post-hoc analysis on negative symptoms. Posters go live on the company website on Oct 11, 2025.
LB Pharmaceuticals (NASDAQ:LBRX) has strengthened its Board of Directors with two strategic appointments following its IPO on September 10, 2025. The company has added William Kane, current President and CEO of Uniquity Bio with extensive commercialization experience, and Rekha Hemrajani, who brings significant financial and operational expertise.
These appointments come at a crucial time as LB Pharmaceuticals prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026. LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.